Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Results of Reevaluation Now Distributed in 4 Ways
December 20, 2004
- DIAGNOSTIC NEWS IN BRIEF
December 20, 2004
- BUSINESS NEWS IN BRIEF -1-
December 20, 2004
- BULLETIN
December 20, 2004
- Very Few Clinical Papers in Japan Suitable as Evidence: Expert
December 13, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 13, 2004
- Dainippon Stresses Need for "Critical Mass" via Merger
December 13, 2004
- Press Seminar
December 13, 2004
- BULLETIN
December 13, 2004
- OTC NEWS IN BRIEF
December 13, 2004
- Schering-Plough Expanding MR Force for New Product Launches: Mr Torii
December 13, 2004
- DIAGNOSTIC NEWS IN BRIEF
December 13, 2004
- JPMA to Amend Charter for Good Corporate Conduct
December 13, 2004
- 3 Qtrs Business Results
December 13, 2004
- BUSINESS NEWS IN BRIEF
December 13, 2004
- Semi-annual Business Results
December 13, 2004
- Semi-annual Business Results
December 13, 2004
- MEDICAL DEVICE NEWS IN BRIEF
December 13, 2004
- 8 Drugs Including PegIntron to Be Added to NHI List
December 13, 2004
- Astellas "1st Step Toward Becoming a Global Mega-pharma": Dr Aoki
December 13, 2004
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…